Biocryst Pharmaceuticals (BCRX) Amortization of Deferred Charges (2011 - 2020)

Biocryst Pharmaceuticals' Amortization of Deferred Charges history runs 10 years deep, the most recent figure standing at $1.4 million for Q4 2020.

• Quarterly Amortization of Deferred Charges rose 299.71% year-over-year to $1.4 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $2.4 million (up 90.07% YoY) and the FY2020 annual result came in at $2.4 million, up 89.98% from the prior year.
• Amortization of Deferred Charges was $1.4 million for Q4 2020 at Biocryst Pharmaceuticals, up from $381000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $1.4 million in Q4 2020 and bottomed at $110000.0 in Q1 2016.
• A 5-year average of $299473.7 and a median of $223000.0 in 2016 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2018 — Amortization of Deferred Charges decreased 4.13% — and 2020, when it surged 299.71%.
• Biocryst Pharmaceuticals' Amortization of Deferred Charges stood at $223000.0 in 2016, then slipped by 2.24% to $218000.0 in 2017, then fell by 4.13% to $209000.0 in 2018, then soared by 63.64% to $342000.0 in 2019, then jumped by 299.71% to $1.4 million in 2020.
• Business Quant data shows BCRX's Amortization of Deferred Charges at $1.4 million in Q4 2020, $381000.0 in Q3 2020, and $341000.0 in Q1 2020.